NICE is unable to make a recommendation about the use in the NHS of NBTXR‑3 for treating advanced soft tissue sarcoma. This is because Nanobiotix does not intend to make an evidence submission for the appraisal. Nanobiotix considers that there is not enough evidence to provide an evidence submission for this appraisal.
If NHS organisations wish to consider NBTXR-3 for treating advanced soft tissue sarcoma, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position if the company decides that it wants to make an evidence submission.